Department of Mechanical Engineering, K. N. Toosi University of Technology, Tehran, Iran.
Department of Mechanical Engineering, K. N. Toosi University of Technology, Tehran, Iran; Advanced Bioengineering Initiative Center, Computational Medicine Center, K. N. Toosi University of Technology, Tehran, Iran; Department of Electrical and Computer Engineering, University of Waterloo, Waterloo, ON, Canada; Centre for Biotechnology and Bioengineering (CBB), University of Waterloo, Waterloo, ON, Canada.
Carbohydr Polym. 2021 Aug 1;265:118027. doi: 10.1016/j.carbpol.2021.118027. Epub 2021 Apr 7.
In this study, magnetic core/chitosan shell Nanoparticles (NPs) containing cisplatin were synthesized via cisplatin complexation with tripolyphosphate as the chitosan crosslinker using two different procedures: a conventional batch flow method and a microfluidic approach. An integrated microfluidic device composed of three stages was developed to provide precise and highly controllable mixing. The comparison of the results revealed that NPs synthesized in microchannels were monodisperse 104 ± 14.59 nm (n = 3) in size with optimal morphological characteristics, whereas polydisperse 423 ± 53.33 nm (n = 3) nanoparticles were obtained by the conventional method. Furthermore, cisplatin was loaded in NPs without becoming inactivated, and the microfluidic technique demonstrated higher encapsulation efficiency, controlled release, and consequently lower IC50 values during exposure to the A2780 cell line proving that microfluidic synthesized NPs were able to enter the cells and release the drug more efficiently. The developed microfluidic platform presents valuable features that could potentially provide the clinical translation of NPs in drug delivery.
在这项研究中，通过使用两种不同的方法：将顺铂与三聚磷酸酯配位作为壳聚糖交联剂，合成了载顺铂的磁性核/壳聚糖纳米粒子（NPs）。开发了一种由三个阶段组成的集成微流控装置，以提供精确和高度可控的混合。结果比较表明，在微通道中合成的 NPs 尺寸为 104±14.59nm（n=3），单分散性好，具有最佳的形态特征，而通过传统方法得到的 NPs 则为多分散性的 423±53.33nm（n=3）。此外，顺铂在 NPs 中被负载而不会失活，并且微流控技术表现出更高的包封效率、控制释放，以及在暴露于 A2780 细胞系时更低的 IC50 值，证明了微流控合成的 NPs 能够更有效地进入细胞并释放药物。所开发的微流控平台具有有价值的特性，有可能为 NPs 在药物输送中的临床转化提供支持。
